1. 1228 Real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab containing regimen in first-line, or sequentially in first- and second-line, from a US private payer perspective. (September 2015) Authors: Johnston, S.; Wilson, K.; Riehle, E.; Varker, H.; Juneau, P.; Sommer, N.; Ogale, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0566 Real World Study of Biologic Disease Modifying Antirheumatic Drug Persistence among Patients with Rheumatoid Arthritis who have Previously used at least One Other Biologic Agent: a U.S. Administrative Claims Database Analysis. (23rd January 2014) Authors: Johnston, S.; McMorrow, D.; Farr, A. M.; Juneau, P.; Ogale, S. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A774 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗